an update on the application of nano-scaled carriers against fluconazole-resistant candida species: nanostructured lipid carriers or solid lipid nanoparticles?

Background and purpose: encapsulation can lead to improved efficacy and safety of antifungal compounds. the attention of scientists has recently turned to biocompatible lipids as the carriers for the delivery of antifungal drugs, such as fluconazole. although several research reports have already been published on fluconazole loaded solid lipid nanoparticles (flz-slns) and fluconazole loaded nanostructured lipid carriers (flz-nlcs), the possible advantages of nlcs over slns have not yet been fully established. studies performed so far have given several contradictory results. materials and methods: both formulations of fluconazole were synthesized using probe ultrasonication method and the characteristics were analyzed. antifungal susceptibility testing (afst) was performed with flz, flz-slns, and flz-nlcs using clsi document m60 against some common fluconazole-resistant candida species. results: a significant decrease was observed in minimum inhibitory concentration values when both formulations were applied. nonetheless, flz-nlcs were significantly more effective (p<0.05). however, three species groups were not statistically different in terms of the activity of flz-nlcs. conclusion: based on the obtained results, flz-nlcs could reverse the azole-resistance phenomenon in the most common candida species more effectively, as compared to flz-slns.